Eli Lilly and Co (LLY)
887.16
+1.61
(+0.18%)
USD |
NYSE |
Oct 04, 16:00
885.89
-1.27
(-0.14%)
Pre-Market: 20:00
Eli Lilly Shareholders Equity (Annual): 10.77B for Dec. 31, 2023
Shareholders Equity (Annual) Chart
Historical Shareholders Equity (Annual) Data
Date | Value |
---|---|
December 31, 2023 | 10.77B |
December 31, 2022 | 10.65B |
December 31, 2021 | 8.979B |
December 31, 2020 | 5.642B |
December 31, 2019 | 2.607B |
December 31, 2018 | 9.829B |
December 31, 2017 | 11.59B |
December 31, 2016 | 14.01B |
December 31, 2015 | 14.57B |
December 31, 2014 | 15.37B |
December 31, 2013 | 17.63B |
December 31, 2012 | 14.77B |
December 31, 2011 | 13.54B |
December 31, 2010 | 12.42B |
December 31, 2009 | 9.524B |
December 31, 2008 | 6.735B |
December 31, 2007 | 13.50B |
December 31, 2006 | 10.98B |
December 31, 2005 | 10.79B |
December 31, 2004 | 10.92B |
Date | Value |
---|---|
December 31, 2003 | 9.765B |
December 31, 2002 | 8.274B |
December 31, 2001 | 7.104B |
December 31, 2000 | 6.047B |
December 31, 1999 | 5.013B |
December 31, 1998 | 4.430B |
December 31, 1997 | 4.646B |
December 31, 1996 | 6.100B |
December 31, 1995 | 5.433B |
December 31, 1994 | 5.356B |
December 31, 1993 | 4.569B |
December 31, 1992 | 4.892B |
December 31, 1991 | 4.966B |
December 31, 1990 | 3.468B |
December 31, 1989 | 3.757B |
December 31, 1988 | 3.225B |
December 31, 1987 | 3.043B |
December 31, 1986 | 2.740B |
December 31, 1985 | 2.388B |
December 31, 1984 | 2.221B |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Annual) Range, Past 5 Years
2.607B
Minimum
2019
10.77B
Maximum
2023
7.730B
Average
8.979B
Median
2021
Shareholders Equity (Annual) Benchmarks
Amgen Inc | 6.232B |
Johnson & Johnson | 68.77B |
Merck & Co Inc | 37.58B |
Pfizer Inc | 89.01B |
Moderna Inc | 13.85B |